We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
REIS
2001
DELISTED
Reis, Inc.
REIS
$441K ﹤0.01%
17,720
ROG icon
2002
Rogers Corp
ROG
$2.46B
$440K ﹤0.01%
7,200
SUM
2003
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
$439K ﹤0.01%
+22,370
New +$447K
ASPS icon
2004
Altisource Portfolio Solutions
ASPS
$65.6M
$438K ﹤0.01%
1,966
-200
-9% -$44.3K
HWC icon
2005
Hancock Whitney
HWC
$6.37B
$438K ﹤0.01%
16,760
PBA icon
2006
Pembina Pipeline
PBA
$28.4B
$438K ﹤0.01%
14,500
-400
-3% -$11.7K
DDS icon
2007
Dillards
DDS
$9.59B
$437K ﹤0.01%
7,204
+1,375
+24% +$89.7K
MDC
2008
DELISTED
M.D.C. Holdings, Inc.
MDC
$435K ﹤0.01%
24,816
+5,853
+31% +$101K
HALO icon
2009
Halozyme
HALO
$11.4B
$433K ﹤0.01%
50,200
+7,900
+19% +$78K
MGA icon
2010
Magna International
MGA
$18.7B
$428K ﹤0.01%
12,267
+1,000
+9% +$40.3K
MTOR
2011
DELISTED
MERITOR, Inc.
MTOR
$428K ﹤0.01%
59,500
ADC icon
2012
Agree Realty
ADC
$9.34B
$427K ﹤0.01%
8,855
+15
+0.2% +$631
BBG
2013
DELISTED
Bill Barrett Corp
BBG
$427K ﹤0.01%
66,812
+9,780
+17% +$71.4K
LRMR icon
2014
Larimar Therapeutics
LRMR
$444M
$426K ﹤0.01%
5,921
-946
-14% -$74.8K
GABC icon
2015
German American Bancorp
GABC
$1.92B
$425K ﹤0.01%
19,940
OMF icon
2016
OneMain Financial
OMF
$7.51B
$425K ﹤0.01%
18,617
+2,210
+13% +$62.5K
POWI icon
2017
Power Integrations
POWI
$3.48B
$425K ﹤0.01%
16,960
AVTA
2018
DELISTED
Avantax, Inc. Common Stock
AVTA
$425K ﹤0.01%
41,050
+16,300
+66% +$128K
CBK
2019
DELISTED
Christopher & Banks Corporation
CBK
$425K ﹤0.01%
193,922
+22,600
+13% +$52.4K
SNCR
2020
DELISTED
Synchronoss Technologies
SNCR
$424K ﹤0.01%
1,478
RSTI
2021
DELISTED
Rofin-Sinar Technologies Inc
RSTI
$424K ﹤0.01%
13,270
GNCMA
2022
DELISTED
GCI Liberty, Inc. Class A-1 Common Stock
GNCMA
$423K ﹤0.01%
26,770
+5,900
+28% +$96.3K
UEIC icon
2023
Universal Electronics
UEIC
$66.6M
$422K ﹤0.01%
5,840
AEL
2024
DELISTED
American Equity Investment Life Holding Company
AEL
$421K ﹤0.01%
29,510
OFLX icon
2025
Omega Flex
OFLX
$291M
$418K ﹤0.01%
11,000
+980
+10% +$34.6K

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.